https://www.cnbc.com/2025/06/18/fda-approves-gilead-hiv-prevention-injection-lenacapavir.html This should be great news, but from a financial, shareholder perspective, there are concerns about cost and availability, with U.S. government programs cutting funding for HIV prevention programs.
Market Data 
Markets 
AI
